Worldwide Trends in Registering Real-World Studies at ClinicalTrials.gov: A Cross-Sectional Analysis

References

• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297. doi:10.1056/NEJMsb1609216
   PubMed Web of Science ®Google Scholar
• NMPA. CfDEo. Real-world data used to generate real-world evidences (Interim); 2021. Available from: http://zhengbiaoke-com.oss-cn-beijing.aliyuncs.com/2104/2104-773f72d9-7fc4-4f02-ae13-ad4aeafc2f98.pdf. Accessed February 11, 2022.
   Google Scholar
• Food and Drug Administration. Real-world evidence. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed July 12, 2022.
   Google Scholar
• Wang B, Lai J, Yan X, Jin F, Yao C. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19. Curr Med Res Opin. 2020;36(7):1131–1135. doi:10.1080/03007995.2020.1771294
   PubMed Web of Science ®Google Scholar
• Wang B, Lai J, Yan X, et al. COVID-19 clinical trials registered worldwide for drug intervention: an overview and characteristic analysis. Drug Des Devel Ther. 2020;14:5097–5108. doi:10.2147/DDDT.S281700
   PubMed Web of Science ®Google Scholar
• Dron L, Kalatharan V, Gupta A, et al. Data capture and sharing in the COVID-19 pandemic: a cause for concern. Lancet Digit Health. 2022;4(10):e748–e756. doi:10.1016/S2589-7500(22)00147-9
   PubMedGoogle Scholar
• Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033–1039. doi:10.1002/pds.4297
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Use of electronic health record data in clinical investigations guidance for industry; 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry. Accessed August 24, 2021.
   Google Scholar
• Gatto NM, Campbell UB, Rubinstein E, et al. The structured process to identify fit-for-purpose data: a data feasibility assessment framework. Clin Pharmacol Ther. 2022;111(1):122–134. doi:10.1002/cpt.2466
   PubMed Web of Science ®Google Scholar
• Gatto NM, Reynolds RF, Campbell UB. A structured preapproval and postapproval comparative study design framework to generate valid and transparent real-world evidence for regulatory decisions. Clin Pharmacol Ther. 2019;106(1):103–115. doi:10.1002/cpt.1480
   PubMed Web of Science ®Google Scholar
• Maruszczyk K, Aiyegbusi OL, Cardoso VR, et al. Implementation of patient-reported outcome measures in real-world evidence studies: analysis of ClinicalTrials.gov records (1999–2021). Contemp Clin Trials. 2022;120:106882. doi:10.1016/j.cct.2022.106882
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Rassen JA, Brown JS, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398–406. doi:10.7326/M18-3079
   PubMed Web of Science ®Google Scholar
• Penberthy LT, Rivera DR, Lund JL, Bruno MA, Meyer AM. An overview of real-world data sources for oncology and considerations for research. CA Cancer J Clin. 2022;72(3):287–300. doi:10.3322/caac.21714
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou C, Feng X, Mo M, Shen J, Zheng Y. Comparison of cancer incidence and mortality between China and the United States. Precis Cancer Med. 2021;4:1.
   Google Scholar
• Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2007;12(1):20–37. doi:10.1634/theoncologist.12-1-20
   PubMed Web of Science ®Google Scholar
• Concato J, Corrigan-Curay J. Real-world evidence - where are we now? N Engl J Med. 2022;386(18):1680–1682. doi:10.1056/NEJMp2200089
   PubMed Web of Science ®Google Scholar
• Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201–1212. doi:10.1002/pds.4932
   PubMed Web of Science ®Google Scholar
• Taur SR. Observational designs for real-world evidence studies. Perspect Clin Res. 2022;13(1):12–16. doi:10.4103/picr.picr_217_21
   PubMedGoogle Scholar
• Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database–update and key issues. N Engl J Med. 2011;364(9):852–860. doi:10.1056/NEJMsa1012065
   PubMed Web of Science ®Google Scholar
• Pranic S, Marusic A. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles. J Clin Epidemiol. 2016;70:26–37. doi:10.1016/j.jclinepi.2015.07.007
   PubMed Web of Science ®Google Scholar
• Nicholls SG, Carroll K, Hey SP, et al. A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing. J Clin Epidemiol. 2021;137:45–57. doi:10.1016/j.jclinepi.2021.03.021
   PubMed Web of Science ®Google Scholar
• Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207. doi:10.7326/0003-4819-158-3-201302050-00583
   PubMed Web of Science ®Google Scholar
• National Evaluation System for health Technology Coordinating Center for Drug Evaluation N. NESTcc research methods and data quality frameworks; 2020. Available from: https://nestcc.org/data-quality-and-methods/. Accessed July 14, 2022.
   Google Scholar
• Xia AD, Schaefer CP, Szende A, Jahn E, Hirst MJ. RWE Framework: An interactive visual tool to support a real-world evidence study design. Drugs Real World Outcomes. 2019;6(4):193–203. doi:10.1007/s40801-019-00167-6
   PubMedGoogle Scholar
• Wang SV, Pinheiro S, Hua W, et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372:m4856. doi:10.1136/bmj.m4856
   PubMed Web of Science ®Google Scholar
• Burcu M, Manzano-Salgado CB, Butler AM, Christian JB. A framework for extension studies using real-world data to examine long-term safety and effectiveness. Ther Innov Regul Sci. 2022;56(1):15–22. doi:10.1007/s43441-021-00322-8
   PubMed Web of Science ®Google Scholar
• Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172(12):819–821. doi:10.7326/M20-1223
   PubMed Web of Science ®Google Scholar
• Piller C, Travis J. Authors, elite journals under fire after major retractions. Science. 2020;368(6496):1167–1168. doi:10.1126/science.368.6496.1167
   PubMed Web of Science ®Google Scholar
• Wang B, Lai J, Yan X, Jin F, Yao C. Exploring the characteristics, global distribution and reasons for retraction of published articles involving human research participants: a literature survey. Eur J Intern Med. 2020;78:145–146. doi:10.1016/j.ejim.2020.03.016
   PubMed Web of Science ®Google Scholar
• Shah K, Charan J, Sinha A, Saxena D. Retraction rates of research articles addressing COVID-19 pandemic: is it the evolving COVID epidemiology or scientific misconduct? Indian J Community Med. 2021;46(2):352–354. doi:10.4103/ijcm.IJCM_732_20
   PubMed Web of Science ®Google Scholar
• Soltani P, Patini R. Retracted COVID-19 articles: a side-effect of the hot race to publication. Scientometrics. 2020;125(1):819–822. doi:10.1007/s11192-020-03661-9
   PubMed Web of Science ®Google Scholar
• Dolgin E. Core concept: the pandemic is prompting widespread use-and misuse-of real-world data. Proc Natl Acad Sci U S A. 2020;117(45):27754–27758. doi:10.1073/pnas.2020930117
   PubMed Web of Science ®Google Scholar
• Wang SV, Schneeweiss S. Assessing and interpreting real-world evidence studies: introductory points for new reviewers. Clin Pharmacol Ther. 2022;111(1):145–149. doi:10.1002/cpt.2398
   PubMed Web of Science ®Google Scholar
• Wang SV, Schneeweiss S. A framework for visualizing study designs and data observability in electronic health record data. Clin Epidemiol. 2022;14:601–608. doi:10.2147/CLEP.S358583
   PubMed Web of Science ®Google Scholar
• Orsini LS, Berger M, Crown W, et al. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Value Health. 2020;23(9):1128–1136. doi:10.1016/j.jval.2020.04.002
   PubMed Web of Science ®Google Scholar
• Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363:k3532. doi:10.1136/bmj.k3532
   PubMed Web of Science ®Google Scholar
• Wang SV, Schneeweiss S, Berger ML, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Pharmacoepidemiol Drug Saf. 2017;26(9):1018–1032. doi:10.1002/pds.4295
   PubMed Web of Science ®Google Scholar
• Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003–1008. doi:10.1016/j.jval.2017.08.3019
   PubMed Web of Science ®Google Scholar
• Wang SV, Verpillat P, Rassen JA, Patrick A, Garry EM, Bartels DB. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin Pharmacol Ther. 2016;99(3):325–332. doi:10.1002/cpt.329
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Moher D, Ehrenstein V, Langan SM. Retraction of COVID-19 pharmacoepidemiology research could have been avoided by effective use of reporting guidelines. Clin Epidemiol. 2020;12:1403–1420. doi:10.2147/CLEP.S288677
   PubMed Web of Science ®Google Scholar
• Desai RJ, Matheny ME, Johnson K, et al. Broadening the reach of the FDA sentinel system: a roadmap for integrating electronic health record data in a causal analysis framework. NPJ Digit Med. 2021;4(1):170. doi:10.1038/s41746-021-00542-0
   PubMed Web of Science ®Google Scholar
• Center. FSI. Innovation Center (IC) master plan; 2021. Available from: https://www.sentinelinitiative.org/news-events/publications-presentations/innovation-center-ic-master-plan. Accessed July 15, 2022.
   Google Scholar
• NMPA. CfDEo. Notice on public comments on the “guidelines for the design and protocol framework of drug real-world study (draft for comment)”; 2022. Available from: https://www.cde.org.cn/main/news/viewInfoCommon/ea778658adc3d1ae3ffe3f1cc0522e5e. Accessed July 15, 2022.
   Google Scholar